



NORTHWEST BIOTHERAPEUTICS

Northwest
Biotherapeutics, Inc.

7600 Wisconsin Avenue
Seventh Floor, Suite 750
Bethesda, MD 20814

www.nwbio.com
OTCBB: NWBT

Media Contact
Linda Powers
240-497-4060

Northwest Biotherapeutics Announces Appointment of Robert A. Farmer to the Board of Directors

BETHESDA, MD. December 10, 2009. Northwest Biotherapeutics, Inc. (“NWBT” or the “Company”) (OTCBB: NWBO) announced today that Robert A Farmer has joined the company’s Board of Directors. Mr. Farmer, a graduate of Dartmouth College and Harvard Law School, currently serves on six other corporate boards.

Mr. Farmer served as the national treasurer of four presidential campaigns, including those of John Kerry, Bill Clinton, Michael Dukakis and John Glenn. In those roles, he led fundraising of over \$800 million. He served under Ron Brown as treasurer of the Democratic National Committee, and served for eight years as treasurer of the Democratic Governor's Association. President Clinton appointed Farmer as the United States Consul General to Bermuda, where he served from 1994 to 1999.

Mr. Farmer also had a successful career as an entrepreneur, with hands-on experience in company building. He built his own publishing company, and sold it in 1983.

“We are delighted to have Bob Farmer join NWBT’s Board,” said Linda Powers, Chair of the Company’s Board of Directors. “Bob has unparalleled experience and networks in the world of fundraising, and he has valuable personal experience in the operational aspects of building successful companies. Both sets of expertise will be of great value in helping to build NWBT as a leader in the new world of cancer vaccines and immune therapies.”

About Northwest Biotherapeutics

Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products that treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis. The Company has two broad platform technologies: dendritic cell-based vaccines and therapeutic antibodies. The Company’s lead clinical trial is a large Phase II trial in GBM. The Company has also received clearance from the FDA for a 600+ patient Phase III trial in prostate cancer, and clearance from the FDA for Phase I trials in five other cancers. The Company has also conducted a Phase I/II trial with DCVax[®] for recurrent metastatic ovarian cancer. The Company’s second technology platform, involving



NORTHWEST BIOTHERAPEUTICS

Northwest
Biotherapeutics, Inc.

7600 Wisconsin Avenue
Seventh Floor, Suite 750
Bethesda, MD 20814

www.nwbio.com
OTCBB: NWBT

antibodies to CXCR4, is at the late pre-clinical development stage.

For further information about clinical sites and Company information please visit the company web site at www.nwbio.com.

Disclaimer

Statements made in this news release that are not historical facts, including statements concerning future treatment of patients with GBM using DCVax[®]-Brain and future clinical trials, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “expects,” “believes,” “intends,” and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those projected in any forward-looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as the Company’s ability to raise additional capital, risks related to the Company’s ability to enroll patients in its clinical trials and complete the trials on a timely basis, the uncertainty of the clinical trials process, uncertainties about the timely performance of third parties, and whether the Company’s products will demonstrate safety and efficacy. Additional information on these and other factors, including Risk Factors, which could affect the Company’s results, is included in its Securities and Exchange Commission (“SEC”) filings. Finally, there may be other factors not mentioned above or included in the Company’s SEC filings that may cause actual results to differ materially from those projected in any forward-looking statement. You should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.